[1]刘胜伟,沈正泽,任忠洋,等.β-石竹烯抗脑缺血/再灌注损伤的网络药理学研究及在体验证[J].西部中医药,2024,37(11):63-69.[doi:10.12174/j.issn.2096-9600.2024.11.14]
　LIU Shengwei,SHEN Zhengze,REN Zhongyang,et al.Network Pharmacology-based Study and In-vivo Verification of β-caryophyllene Against Cerebral Ischemia/Reperfusion Injury[J].Western Journal of Traditional Chinese Medicine,2024,37(11):63-69.[doi:10.12174/j.issn.2096-9600.2024.11.14]
点击复制

β-石竹烯抗脑缺血/再灌注损伤的网络药理学研究及在体验证
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
37
期数:
2024年11期
页码:
63-69
栏目:
二次研究
出版日期:
2024-11-15

文章信息/Info

Title:
Network Pharmacology-based Study and In-vivo Verification of β-caryophyllene Against Cerebral Ischemia/Reperfusion Injury
作者:
刘胜伟1, 沈正泽1, 任忠洋2, 丁玲3, 刘洁3, 陈昶4
1.重庆医科大学附属永川医院，重庆 402160
2.重庆市江津区中医院，重庆 402284
3.重庆市江津区中心医院，重庆 402260
4.重庆医科大学生命科学研究院，重庆 400016
Author(s):
LIU Shengwei1, SHEN Zhengze1, REN Zhongyang2, DING Ling3, LIU Jie3, CHEN Chang4
1.The Affiliated Yongchuan Hospital of Chongqing Medical University, Chongqing 402160, China
2.Jiangjin District Hospital of TCM, Chongqing 402284, China
3.Jiangjin District Central Hospital, Chongqing 402260, China
4.Institute of Life Sciences, Chongqing Medical University, Chongqing 400016, China
关键词:
脑缺血/再灌注损伤; -石竹烯; 网络药理学
Keywords:
cerebral ischemia/reperfusion injury; -caryophyllene; network pharmacology
分类号:
R255.2
DOI:
10.12174/j.issn.2096-9600.2024.11.14
文献标志码:
A
摘要:
目的采用网络药理学方法探索β-石竹烯（β-caryophyllene，BCP）在脑缺血/再灌注损伤（cerebral ischemia-reperfusion injury，CIRI）中发挥作用的潜在机制，并对关键通路中的关键靶点进行验证。 方法通过PharmMapper（pharmmapper server）数据库获得BCP相关靶点；通过人类基因数据库（https：//www.genecards.org/，GeneCards）和在线人类孟德尔遗传数据库（online mendelian inheritance in man，OMIM）数据库获得CIRI的相关靶点；利用VENNY 2.1.0数据库比对筛选BCP抗CIRI的潜在作用靶点，并利用软件Cytoscape 3.7.1绘制相互图；利用软件R语言中的clusterProfiler包对BCP抗CIRI的潜在靶点进行基因本体论（gene ontology，GO）富集分析及京都基因与基因组百科全书（kyoto encyclopedia of genes and genomes，KEGG）富集通路分析；建立大鼠CIRI模型，用western blot法验证BCP抗CIRI的潜在靶点。 结果筛选出BCP相关靶点194个，CIRI相关靶点1144个，共同靶点102个。BCP主要作用于白细胞介素6（interleukin-6，IL-6）、肿瘤坏死因子（tumor necrosis factor，TNF）、肿瘤蛋白p53（tumor protein p53，TP53）、丝裂原活化蛋白激酶1（mitogen-activated protein kinase 1，MAPK1）、信号转导子和转录激活子3（signal transducer and activator of transcription 3，STAT3）、半胱天冬酶3（caspase 3，CASP3）等关键靶点，通过过氧化物酶体增殖物激活受体（peroxisome proliferator-activated receptors，PPAR）、丝裂原活化蛋白激酶（mitogen-activated protein kinase，MAPK）、核因子κB（nuclear factor kappa-B，NF-κB）、P53（tumor protein p53，P53）等信号通路途径，对CIRI发挥抗炎、抗氧化、抗凋亡、神经保护作用。 结论BCP在CIRI治疗中的作用主要涉及抗凋亡、神经保护作用，其他还与抗炎、抗氧化等多靶点、多通路相关，体现出我国中医药多靶点、多环节发挥作用的特点。
Abstract:
ObjectiveTo explore the potential mechanism of β-caryophyllene (BCP) in the treatment of cerebral ischemia/reperfusion injury (CIRI) using network pharmacology, and to confirm the key targets in the key pathway. MethodsBCP related targets were obtained from PharmMapper, CIRI related targets were gained from GeneCards and OMIM, the potential targets of BCP against CIRI were screened using VENNY 2.1.0 database, and PPI was drawn using Cytoscape 3.7.1 software, clusterProfiler package in software R language was utilized to perform GO enrichment analysis and KEGG enrichment pathway analysis of the potential targets of BCP against CIRI, and western blot method was applied to validate the potential targtes of BCP against CIRI after establishing rat models with CIRI. ResultsThe study has filtered 194 BCP related targets, 1144 CIRI related targets and 102 common targets. BCP could exert anti-inflammatory, anti-oxidant, anti-apoptotic and neuroprotective effects on CIRI mainly through acting on the key targets including IL-6, TNF, TP53, MAPK1, STAT3 and CASP3, as well as the signaling pathways such as PPAR, MAPK, NF-κB, and p53. ConclusionBCP mainly develops the anti-apoptotic and neuroprotective effects in the treatment of CIRI, and others are related to multiple targets and pathways such as anti-inflammatory and antioxidant, embodying the characteristics of multi-target and multi-link effects of TCM in China.

备注/Memo

备注/Memo:
刘胜伟（1985—），男，硕士学位，主管药师。研究方向：中药药理学、生物信息学等。国家自然科学基金青年科学基金项目（81701477）；重庆市科卫联合中医药技术创新与应用发展项目（2021ZY3591）；重庆市永川区科学技术局2022年度公益类科研项目（2022yc-jckx20055）；重庆医科大学附属永川医院2020年度院内科研课题资助项目（YJJC202009）；重庆医科大学附属永川医院2021年度院内科研课题资助项目（YJSJ202132）。
更新日期/Last Update: 2024-11-15